Tower Research Capital (TRC)’s Pasithea Therapeutics KTTA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.04K Sell
6,176
-2,662
-30% -$1.34K ﹤0.01% 4975
2026
Q2
$4.56K Buy
8,838
+6,984
+377% +$4.8K ﹤0.01% 4375
2026
Q1
$1.38K Sell
1,854
-1,093
-37% -$914 ﹤0.01% 4678
2025
Q4
$3.8K Buy
2,947
+1,730
+142% +$1.52K ﹤0.01% 4312
2025
Q3
$891 Sell
1,217
-44
-3% -$32 ﹤0.01% 4911
2025
Q2
$910 Sell
1,261
-2,006
-61% -$2.19K ﹤0.01% 4914
2025
Q1
$4.25K Buy
3,267
+1,381
+73% +$2.45K ﹤0.01% 4282
2024
Q4
$5.94K Buy
1,886
+1,285
+214% +$4.55K ﹤0.01% 4222
2024
Q3
$3.26K Sell
601
-1,206
-67% -$5.94K ﹤0.01% 4875
2024
Q2
$9.14K Buy
1,807
+462
+34% +$3.02K ﹤0.01% 4284
2024
Q1
$9.8K Buy
1,345
+725
+117% +$5.15K ﹤0.01% 3797
2023
Q4
$4.59K Sell
620
-5
-0.8% -$37 ﹤0.01% 4939
2023
Q3
$6K Buy
625
+1
+0.2% +$11 ﹤0.01% 4656
2023
Q2
$6.12K Sell
624
-6
-1% -$48 ﹤0.01% 4736
2023
Q1
$5K Sell
630
-122
-16% -$1.38K ﹤0.01% 4973
2022
Q4
$10K Buy
752
+469
+166% +$9.37K ﹤0.01% 4022
2022
Q3
$7K Buy
283
+170
+150% +$3.99K ﹤0.01% 4896
2022
Q2
$2K Buy
+113
New +$2.4K ﹤0.01% 5559
2022
Q1
– Sell
-1,469
Closed -$52K – 6347
2021
Q4
$52K Buy
1,469
+1,377
+1,497% +$71.6K ﹤0.01% 2732
2021
Q3
$6K Buy
+92
New +$5.58K ﹤0.01% 4760

Other funds holding KTTA

Tower Research Capital (TRC)'s KTTA Position: Q3 2026 in Review

Tower Research Capital (TRC) reduced its Pasithea Therapeutics (KTTA) stake by 30% in Q3 2026, selling an estimated $1.34K and leaving 6,176 shares worth $3.04K. The position accounts for ﹤0.01% of the portfolio, ranked #4975.

Tower Research Capital (TRC) first reported a position in KTTA in Q3 2021 and has held it in 20 quarters since. The position peaked at $52K in Q4 2021. 26 funds tracked by Wall St. Rank hold KTTA as of Q3 2026.

  • Tower Research Capital (TRC) held 6,176 shares of Pasithea Therapeutics worth $3.04K as of Q3 2026.
  • Tower Research Capital (TRC) sold 2,662 Pasithea Therapeutics shares in Q3 2026, an estimated $1.34K.
  • Pasithea Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q3 2026, its #4975 holding.
  • Tower Research Capital (TRC) first reported a position in Pasithea Therapeutics in Q3 2021 and has held it in 20 quarters since.
  • Tower Research Capital (TRC)'s Pasithea Therapeutics position peaked at $52K in Q4 2021.
  • 26 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q3 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2026, filed 16 Nov 2026.